Results 71 to 80 of about 3,887,212 (164)

Secondary acute myeloid leukaemia after peptide receptor radionuclide therapy

, 2011
Peptide receptor radionuclide therapy (PRRT) with 90Y-DOTATOC or 177Lu-DOTATATE has demonstrated its efficacy in the treatment of neuroendocrine- and somatostatin-receptor expressing tumours .
Andrea Piccin, Irene Pusceddu, Piccin, Andrea, Sergio Cortelazzo, Chiara Maria Grana, Giovanni Negri, Paganelli, Giovanni, Giovanni Paganelli, Cortelazzo, Sergio, Negri, Giovanni, Grana, Chiara Maria, Pusceddu, Irene   +11 more
core   +1 more source

A Rapid and Safe Infusion Protocol for Lu-177 Peptide Receptor Radionuclide Therapy

, 2021
Peptide receptor radionuclide therapy (PRRT) with 177Lu-labeled somatostatin analogs in patients with somatostatin receptor-expressing tumors is often performed using administration protocols prescribing a 30-min infusion time. The most often used method
Barentsz, Maarten W, de Keizer, Bart, Lam, Marnix G E H, Ebbers, Sander C, Braat, Arthur J A T, Krijger, Gerard C   +5 more
core  

GPCRs in CAR‐T Cell Immunotherapy: Expanding the Target Landscape and Enhancing Therapeutic Efficacy

Advanced Science, Volume 13, Issue 35, 24 June 2026.
Chimeric antigen receptor T cell therapy faces dual challenges of target scarcity and an immunosuppressive microenvironment in solid tumors. This review highlights how G protein‐coupled receptors can serve as both novel targets to expand the therapeutic scope and functional modules to enhance CAR‐T cell efficacy.
Zhuoqun Liu, Yuchen Xiao, Yamin Zhao, Lihe Dai, David J.H. Shih, Shikang Liang, Honglei Tian, Liu Liu, Feng Tian, Bing Liu, Lei Chang, Chao Zhang   +11 more
wiley   +1 more source

Figure S1 from The Role of Adding Somatostatin Analogues to Peptide Receptor Radionuclide Therapy as a Combination and Maintenance Therapy

, 2018
Consort diagram of the study population. At the beginning of the analyses 421 patients, treated with peptide receptor radionuclide therapy (PRRT), were assessed. Patients who did not meet the inclusion criteria were excluded.
Maria A. Gonzalez-Carmona (9406151), Peter Brossart (640482), Markus Essler (344421), Karin Mayer (15012672), Christian P. Strassburg (7162190), Rolf Fimmers (271452), Hojjat Ahmadzadehfar (714757), Anna Yordanova (15012666), Marcel M. Wicharz (15012669)   +8 more
core   +1 more source

Neuroendocrine tumours through an epigenetic lens: Emerging insights for diagnosis and treatment

Journal of Neuroendocrinology, Volume 38, Issue 6, June 2026.
Abstract Neuroendocrine tumours (NETs) are well‐differentiated epithelial neuroendocrine neoplasms that frequently develop in the small intestine, pancreas, and lungs. NETs originate from neuroendocrine cells specialized in hormone secretion implicated in a number of physiological processes.
Victoria Jacquot, Benjamin Chevalier, Thomas Walter, Benjamin Gibert, Maria Ouzounova   +4 more
wiley   +1 more source

New Developments in Peptide Receptor Radionuclide Therapy

, 2019
Peptide Receptor Radionuclide Therapy (PRRT) is an established treatment for non-operable or metastatic neuroendocrine neoplasms that express highly and frequently somatostatin receptors.
NICOLAS Guillaume, SCHOTTELIUS Margret, FANI Melpomeni, MORGENSTERN Alfred   +3 more
core   +1 more source

Metastatic large cell neuroendocrine carcinoma of larynx: Individualizing tumor biology by dual tracer positron emission tomography/computed tomography (68Ga-DOTATATE and 18F-fluorodeoxyglucose) molecular imaging and disease stabilization following 177Lu-DOTATATE peptide receptor radionuclide therapy after initial progression on chemoradiotherapy

World Journal of Nuclear Medicine, 2019
Debate exists on the disease biology and course of primary large cell neuroendocrine carcinoma (LCNEC) of larynx, being classified as a variant of atypical carcinoid by the World Health Organisation-2005 classification, while literature of its aggressive
Sonali Jadhav, Sandip Basu
doaj   +1 more source

Five Advances in the Last 50 Years That Have Impacted Endocrine Surgery

World Journal of Surgery, Volume 50, Issue 8, Page 2071-2076, August 2026.
Matilda Anneback, Priya H. Dedhia, Aimee Di Marco, Els Nieveen van Dijkum, Julie A. Miller, Janice L. Pasieka   +5 more
wiley   +1 more source

Visualized Clinical‐Radiomics Model Based on Non‐Contrast Computed Tomography for Predicting Efficacy of Surufatinib in Hepatic Metastases of Neuroendocrine Neoplasms

Cancer Medicine, Volume 15, Issue 5, May 2026.
NCCT radiomics for surufatinib efficacy prediction in HM‐NENs. ABSTRACT Background Hepatic metastatic neuroendocrine neoplasms (HM‐NENs) have few treatment biomarkers and low survival rates. We created a clinical‐radiomics fusion model based on non‐contrast computed tomography (NCCT) to predict Surufatinib efficacy in HM‐NENs.
Miaomiao Feng, Man Zhao, Xiaoling Duan, Jiaojiao Hou, Qi Wang, Fei Yin   +5 more
wiley   +1 more source

Safety and Efficacy of Peptide-Receptor Radionuclide Therapy in Elderly Neuroendocrine Tumor Patients

, 2021
Peptide receptor radionuclide therapy (PRRT) is a well-established treatment in somatostatin receptor-expressing neuroendocrine tumours (NETs). The safety and efficacy of PRRT in >79 years old patients (EP) have not been systematically investigated ...
Marco Cattaneo, Guillaume P. Nicolas, Lawrence O. Dierickx, Peter Igaz, Deborah Theiler, Emanuel Christ, Simona Grozinsky-Glasberg, Claire Bournaud, M. Sue O’Dorisio, Damian Wild, Thomas O’Dorisio   +10 more
core   +1 more source